ERBB2 and neoplasm: In the late phase of PBMC-humanized tumor xenograft disease model, the BsAb showed superior tumor inhibition compared with mAb and combination therapies, possibly through the inhibition of HER2 signaling, blockade of PD-L1/PD-1 signaling, and enhanced ADCC.